Inhaltsbereich
| 27 Einträge | 1, 2 › » |
Seite 1 / 2
 Druckansicht
|
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. |
| Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W |
| The American journal of gastroenterology. doi: 10.14309/ajg.0000000000000617. pii: 00000434-202008000-00022 |
| PMID: 32759621 |
| Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. |
| Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS |
| Journal of Crohn's & colitis. 2021 Oct 19. pii: 6401649. doi: 10.1093/ecco-jcc/jjab183 |
| PMID: 34664635 |
| Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab. |
| Dulai PS, Wong ECL, Reinisch W, Colombel JF, Marshall JK, Narula N |
| Inflammatory bowel diseases. 2021 Dec 30. pii: 6490022. doi: 10.1093/ibd/izab310 |
| PMID: 34967397 |
| Categorizing Endoscopic Severity of Crohn's Disease Using the Modified Multiplier SES-CD (MM-SES-CD). |
| Narula N, Pray C, Wong ECL, Colombel JF, Marshall JK, Daperno M, Reinisch W, Dulai PS |
| Journal of Crohn's & colitis. 2022 Feb 3. pii: 6520897. doi: 10.1093/ecco-jcc/jjac018 |
| PMID: 35134140 |
| Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease. |
| Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N |
| Alimentary pharmacology & therapeutics. 2022 Feb 15. doi: 10.1111/apt.16805 |
| PMID: 35166396 |
| Editorial: is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply. |
| Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N |
| Alimentary pharmacology & therapeutics. doi: 10.1111/apt.16866 |
| PMID: 35362140 |
| Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease. |
| Narula N, Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W |
| The American journal of gastroenterology. 2022 Apr 15. doi: 10.14309/ajg.0000000000001795. pii: 00000434-990000000-00336 |
| PMID: 35435862 |
| Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19. |
| Einstein AJ, Hirschfeld C, Williams MC, Vitola JV, Better N, Villines TC, Cerci R, Shaw LJ, Choi AD, Dorbala S, Karthikeyan G, Lu B, Sinitsyn V, Ansheles AA, Kudo T, Bucciarelli-Ducci C, Nørgaard BL, Maurovich-Horvat P, Campisi R, Milan E, Louw L, Allam AH, Bhatia M, Sewanan L, Malkovskiy E, Cohen Y, Randazzo M, Narula J, Morozova O, Pascual TNB, Pynda Y, Dondi M, Paez D |
| Journal of the American College of Cardiology. pii: S0735-1097(22)04561-2. doi: 10.1016/j.jacc.2022.03.348 |
| PMID: 35589162 |
| The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn's Disease. |
| Narula N, Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W |
| Inflammatory bowel diseases. 2022 Jun 28. pii: 6619085. doi: 10.1093/ibd/izac130 |
| PMID: 35762666 |
| Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease. |
| Wong ECL, Yusuf A, Pokryszka J, Dulai PS, Colombel JF, Marshall JK, Reinisch W, Narula N |
| Inflammatory bowel diseases. 2022 Jul 26. pii: 6650010. doi: 10.1093/ibd/izac157 |
| PMID: 35880680 |
| End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis. |
| Wong ECL, Hasan B, Dulai PS, Marshall JK, Reinisch W, Narula N |
| Scandinavian journal of gastroenterology. 2022 Jul 30. doi: 10.1080/00365521.2022.2105169 |
| PMID: 35909369 |
| Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease. |
| Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N |
| Inflammatory bowel diseases. 2022 Aug 3. pii: 6654444. doi: 10.1093/ibd/izac168 |
| PMID: 35920382 |
| Time to endorse a sensitive method for scoring endoscopic activity of ulcerative colitis in clinical research. |
| Narula N, Merat S, Liu D, Pugatch D, Reinisch W |
| Journal of Crohn's & colitis. 2022 Aug 24. pii: 6674697. doi: 10.1093/ecco-jcc/jjac120 |
| PMID: 36001709 |
| Predictors of Placebo Induction Response and Remission in Ulcerative Colitis. |
| Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N |
| Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2022 Aug 24. pii: S1542-3565(22)00811-4. doi: 10.1016/j.cgh.2022.08.015 |
| PMID: 36029969 |
| Long-term Outcomes of Early Versus Delayed Responders to Vedolizumab and Adalimumab: A Post-hoc Analysis of VARSITY. |
| Narula N, Wong ECL, Marshall JK, Jairath V, Dulai PS, Reinisch W |
| The American journal of gastroenterology. 2022 Sep 1. doi: 10.14309/ajg.0000000000001987. pii: 00000434-990000000-00494 |
| PMID: 36066459 |
| Pilot study of an elimination diet in adults with mild to moderate Crohn's disease. |
| Narula N, Wong ECL, Moayyedi P, Reinisch W, Marshall JK |
| European journal of gastroenterology & hepatology. 2022 Sep 12. doi: 10.1097/MEG.0000000000002438. pii: 00042737-990000000-00060 |
| PMID: 36165053 |
| Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis. |
| Pray C, Wong ECL, Aruljothy A, Dulai PS, Marshall JK, Reinisch W, Narula N |
| Inflammatory bowel diseases. 2022 Sep 30. pii: 6732190. doi: 10.1093/ibd/izac210 |
| PMID: 36179118 |
| Baseline Patient-reported Symptoms Less Predictive Than MM-SES-CD for Endoscopic Remission in Crohn's Disease. |
| Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W |
| Journal of clinical gastroenterology. 2022 Oct 11. doi: 10.1097/MCG.0000000000001774. pii: 00004836-990000000-00073 |
| PMID: 36227009 |
| Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's Disease. |
| Wong ECL, Dulai PS, Marshall JK, Jairath V, Reinisch W, Narula N |
| Inflammatory bowel diseases. 2022 Nov 25. doi: 10.1093/ibd/izac231. pii: 6847060 |
| PMID: 36426810 |
| 27 Einträge | 1, 2 › » |
Seite 1 / 2
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
